13F-HR filed by Cormorant Asset Management, LP
Cormorant Asset Management, LP filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-14, with 45 holding rows worth $1,885,759,705.
- Accession
- 0001583977-24-000006
- Filer
- CIK 1583977
- Filed
- 2024-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2024
A holdings report, 45 entries on the cover page, a total value of $1,885,759,705 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,885,759,705 with VALUE read as dollars as filed, 13F file number 028-15949. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerChen Bihua028-15950
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 8,494,151 | $428,275,093 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 1,000,000 | $114,270,000 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 1,250,000 | $104,387,500 | dollars as filed | |
| LONGBOARD PHARMACEUTICALS IN | 54300N103 | COM | 2,790,462 | $93,006,098 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 3,406,534 | $90,920,392 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 8,325,000 | $66,516,750 | dollars as filed | |
| RAPPORT THERAPEUTICS INC COM | 75383L102 | Stock | 2,940,921 | $60,230,062 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 1,100,000 | $56,210,000 | dollars as filed | |
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 870,000 | $50,059,800 | dollars as filed | |
| CORBUS PHARMACEUTICALS | 21833P301 | COM NEW | 2,375,000 | $48,996,250 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 1,050,000 | $48,226,500 | dollars as filed | |
| JANUX THERAPEUTICS INC | 47103J105 | COM | 1,050,000 | $47,701,500 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 1,858,351 | $47,313,616 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 2,470,000 | $41,002,000 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 2,561,600 | $40,959,984 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 740,000 | $36,970,400 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 975,000 | $36,786,750 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 500,000 | $36,500,000 | dollars as filed | |
| BIOMEA FUSION INC | 09077A106 | CMN | 3,570,872 | $36,065,807 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 400,000 | $35,948,000 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 1,629,529 | $33,894,203 | dollars as filed | |
| HELIX ACQUISITION CORP II | G4444H101 | CL A ORD SHS | 2,909,000 | $30,398,759 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 1,466,460 | $27,158,839 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 2,130,000 | $24,537,600 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 2,147,396 | $22,934,189 | dollars as filed | |
| CARGO THERAPEUTICS INC COM | 14179K101 | Stock | 1,182,563 | $21,818,287 | dollars as filed | |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | COM | 2,325,000 | $21,622,500 | dollars as filed | |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 400,000 | $20,956,000 | dollars as filed | |
| BIOHAVEN LTD | G1110E107 | COM | 401,963 | $20,086,091 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 1,550,000 | $19,685,000 | dollars as filed | |
| Y-mAbs Therapeutics Inc | 984241109 | Common Stock | 1,450,000 | $19,067,500 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 700,000 | $18,186,000 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 500,000 | $16,445,000 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 585,462 | $13,758,357 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 342,465 | $11,472,578 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 265,826 | $8,883,905 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 400,000 | $7,272,000 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M105 | COM | 1,000,000 | $6,600,000 | dollars as filed | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 427,163 | $5,249,833 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 107,344 | $4,504,154 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 593,043 | $3,967,458 | dollars as filed | |
| VYNE THERAPEUTICS INC | 92941V308 | COM | 1,394,336 | $2,621,352 | dollars as filed | |
| VERVE THERAPEUTICS INC | 92539P101 | COM | 350,000 | $1,694,000 | dollars as filed | |
| ARTIVA BIOTHERAPEUTICS INC | 04317A107 | COM | 103,633 | $1,601,130 | dollars as filed | |
| RAPT THERAPEUTICS INC | 75382E109 | COM | 496,750 | $998,468 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001583977-24-000006 | this filing | 2024-11-14 | acceptance time not in the bulk data set |